BioHarvest Sciences (NASDAQ:BHST – Get Free Report) and Solesence (NASDAQ:SLSN – Get Free Report) are both small-cap consumer staples companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.
Insider & Institutional Ownership
70.2% of Solesence shares are held by institutional investors. 4.8% of Solesence shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Risk & Volatility
BioHarvest Sciences has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Solesence has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.
Earnings & Valuation
This table compares BioHarvest Sciences and Solesence”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioHarvest Sciences | $34.51 million | 1.02 | -$11.14 million | ($0.52) | -3.44 |
| Solesence | $55.37 million | 1.11 | $1.79 million | ($0.03) | -29.00 |
Solesence has higher revenue and earnings than BioHarvest Sciences. Solesence is trading at a lower price-to-earnings ratio than BioHarvest Sciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares BioHarvest Sciences and Solesence’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioHarvest Sciences | -31.21% | -58.30% | -25.60% |
| Solesence | -3.40% | -11.58% | -3.79% |
Analyst Recommendations
This is a breakdown of current ratings and price targets for BioHarvest Sciences and Solesence, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioHarvest Sciences | 1 | 0 | 2 | 0 | 2.33 |
| Solesence | 1 | 0 | 0 | 0 | 1.00 |
BioHarvest Sciences currently has a consensus price target of $6.50, suggesting a potential upside of 263.13%. Given BioHarvest Sciences’ stronger consensus rating and higher probable upside, equities analysts clearly believe BioHarvest Sciences is more favorable than Solesence.
Summary
Solesence beats BioHarvest Sciences on 10 of the 14 factors compared between the two stocks.
About BioHarvest Sciences
BioHarvest Sciences Inc. is a biotechnology company developing health and wellness products through its proprietary Botanical Synthesis technology. The platform is designed to produce plant-based compounds in controlled environments without relying on conventional agricultural cultivation of the whole plant, with the goal of preserving targeted botanical molecules and improving production consistency. The company’s primary commercial product is VINIA, a dietary supplement made from a proprietary red grape cell culture and marketed for its polyphenol content and potential cardiovascular and general wellness benefits.
About Solesence
Solesence is a skincare company focused on developing science-based products designed to protect, improve and maintain the health and appearance of skin. Its work centers on combining cosmetic formulations with dermatological and cosmetic science, particularly in areas such as daily skin protection and visible signs of skin aging. The company develops skincare and sun-care formulations for use in branded and private-label products. Its offerings are intended to support needs including mineral sun protection, hydration, skin tone and texture, and anti-aging care.
Receive News & Ratings for BioHarvest Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioHarvest Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
